Ionis Pharmaceuticals (NASDAQ: IONS) insider plans $138,963 Rule 144 share sale

Rhea-AI Filing Summary

Ionis Pharmaceuticals filed a notice of proposed insider share sales under Rule 144. The filing covers 1,823 shares of common stock to be sold through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $138,963.60. The issuer reports 161,137,930 shares of common stock outstanding.

The shares to be sold were acquired as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation, with both the grant and payment dated 01/15/2026. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Ionis Pharmaceuticals’ operations.

Insights

Insider transactions and securities law analyst

Routine Rule 144 filing for a modest insider equity-compensation sale.

This notice covers a proposed sale of 1,823 shares of Ionis Pharmaceuticals common stock under Rule 144, with an aggregate market value of $138,963.60. The broker listed is Morgan Stanley Smith Barney, and the shares are to be sold on NASDAQ. The size is small compared with the 161,137,930 shares outstanding.

The shares were acquired via RSUs granted under the 2011 Equity Incentive Plan as compensation, which is a standard mechanism for employee or executive equity awards. Rule 144 provides a safe harbor for resales of restricted or control securities, subject to conditions on holding period, volume, and manner of sale.

The signer represents they do not know of any material adverse information about current or prospective operations that has not been publicly disclosed, which is typical language designed to address insider trading concerns. Overall, this appears to be a routine administrative step for a relatively small planned sale, without additional information about company fundamentals in this excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	1823	138963.60	161137930	01/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			1823	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Ionis Pharmaceuticals (IONS) Form 144 filing disclose?

It discloses a planned sale of 1,823 shares of Ionis Pharmaceuticals common stock under Rule 144, with an aggregate market value of $138,963.60, to be executed through Morgan Stanley Smith Barney on NASDAQ.

How were the Ionis Pharmaceuticals (IONS) shares being sold acquired?

The shares were acquired as RSUs granted under the 2011 Equity Incentive Plan of Ionis Pharmaceuticals, with the acquisition and payment noted as 01/15/2026 and characterized as compensation.

How large is the planned Ionis Pharmaceuticals (IONS) share sale relative to shares outstanding?

The notice covers 1,823 shares of common stock, while the company reports 161,137,930 shares of common stock outstanding, indicating a relatively small transaction size compared with total shares.

Which broker and exchange are involved in the Ionis Pharmaceuticals (IONS) Rule 144 sale?

The filing lists Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036, as the broker, and identifies NASDAQ as the securities exchange where the common stock is to be sold.

What representation does the seller make in the Ionis Pharmaceuticals (IONS) Form 144?

By signing, the seller represents that they do not know any material adverse information about the current and prospective operations of Ionis Pharmaceuticals that has not been publicly disclosed.

What is the purpose of Rule 144 in the context of Ionis Pharmaceuticals (IONS)?

Rule 144 provides a framework for reselling restricted or control securities. In this case, it is used to give notice of a proposed sale of Ionis Pharmaceuticals common stock acquired through equity compensation.